Comparison of peak serum C-reactive protein and hydroxybutyrate dehydrogenase levels in patients with acute myocardial infarction treated with alteplase and streptokinase.
Peak serum C-reactive protein concentrations were measured in 146 patients randomized to receive streptokinase, alteplase, or a combination of streptokinase and alteplase in the GUSTO-I trial. Those receiving alteplase treatment had lower values than those receiving streptokinase or the combination treatment. Irrespective of treatment, complete reperfusion of the infarct-related artery (TIMI grade 3 flow) was associated with low peak serum C-reactive protein values.
Pietilä
K
K
Clinic of Internal Medicine, Department of Clinical Sciences, Tampere University, Finland.
Hermens
W T
WT
Harmoinen
A
A
Baardman
T
T
Pasternack
A
A
Topol
E J
EJ
Simoons
M L
ML
D000368:Aged; D002097:C-Reactive Protein / Q000378:metabolism*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006884:Hydroxybutyrate Dehydrogenase / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood* / Q000188:drug therapy; D013300:Streptokinase / Q000627:therapeutic use*; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*
D002097:C-Reactive Protein; D006884:Hydroxybutyrate Dehydrogenase; D013300:Streptokinase; D010959:Tissue Plasminogen Activator